HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $26

Benzinga · 05/10 12:11
HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $24 to $26.